Rasna Therapeutics, Inc. OTC:RASP , a development stage biotechnology company focused on the development of cancer drugs, today announced the successful completion of its merger. Rasna Therapeutics, Inc. is a development stage biotechnology company focused primarily on the development of drug candidates for leukemia and lymphoma. Abnormal epigenetic modification is recognized to play an important role in the pathogenesis of acute myeloid leukemia AML , leading to silencing of genes involved in tumor suppression and cellular reproduction. Rasna s focus on inhibition of lysine specific demethylase LSD , an enzyme involved in epigenetic control, represents a promising and novel approach towards AML. Rasna has developed novel irreversible and reversible LSD regulators that have shown appropriate effects on the LSD gene in vitro and in IND enabling pre clinical studies.
Quote | Rasna Therapeutics Inc. (OTCMKTS:RASP)
Last: | $0.0077 |
---|---|
Change Percent: | 0.0% |
Open: | $0.0077 |
Close: | $0.0077 |
High: | $0.0077 |
Low: | $0.0077 |
Volume: | 250 |
Last Trade Date Time: | 02/12/2024 03:00:00 am |
News | Rasna Therapeutics Inc. (OTCMKTS:RASP)
Message Board Posts | Rasna Therapeutics Inc. (OTCMKTS:RASP)
Subject | By | Source | When |
---|---|---|---|
RASP .008 | Longer Than Most | investorshub | 04/13/2023 5:12:30 PM |
We need buyers to tighten it up and | splintered sunlight | investorshub | 03/07/2023 5:08:18 PM |
The gap is huge on this one. | Gnarlyman | investorshub | 03/07/2023 3:04:08 PM |
Bids building | splintered sunlight | investorshub | 03/03/2023 7:56:29 PM |
hopefully - so far no volume | splintered sunlight | investorshub | 03/03/2023 3:44:44 PM |